This post in response to srinsocal post# 346307 on
Post# of 8896
This is HUGE. In all probability, Electrome has already taken a good, hard look at BIEL’s vagus nerve utility patent application. The pr was issued on 21 May 2024, about year and a half ago. Here’s a quote from the pr.
Quote:https://www.newmediawire.com/news/bioelectron...ng-7075138 - According to Investopedia and the USPTO the following is true …
Although vagus nerve stimulation has been shown to suppress pro-inflammatory cytokine levels in the periphery, traditional stimulation techniques are not suitable for chronic vagus nerve stimulation.
BioElectronics’ PSWT technology and device designs overcome this limitation, providing a convenient, economical, and highly effective alternative for treating chronic inflammation. Given that over one-third of Americans suffer from chronic, systemic inflammation, this development opens an ENORMOUS new market opportunity for BioElectronics.
Quote:"Vagus nerve and Atherosclerosis" search on DuckDuckGo - these are the results
A utility patent application is a legal document filed with the United States Patent and Trademark Office (USPTO) to seek protection for a new or improved invention, such as a product, process, or machine. This application grants the inventor exclusive rights to their invention for up to 20 years, preventing others from making, using, or selling it without permission.
** https://duckduckgo.com/?q=vagus+nerve+and+ath...amp;ia=web
Lots of interest in this field of Cardiovascular medicine and PEMF stimulation of the vagus nerve. Coming up w/ a new treatment modality for this (and others) is a real game-changer.
Quote:"Sic parvis magna" - Greatness from small beginnings
THESE are the times that try men’s souls. The summer soldier and the sunshine patriot will, in this crisis, shrink from the service of their country; but he that stands it now, deserves the love and thanks of man and woman.
All the best, WBeacham